

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Sunil Chada *et al.*

Serial No.: 10/017,472

Filed: December 7, 2001


For: METHODS OF TREATMENT
INVOLVING HUMAN MDA-7

Group Art Unit: 1633

Examiner: Li, Qian Janice

Atty. Dkt. No.: INGN:097US

Confirmation No.: 5209

CERTIFICATE OF ELECTRONIC TRANSMISSION 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:	
February 26, 2007 Date	 Travis Wohlers

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/INGN:097US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Travis Wohlers
Reg. No. 57,423
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 26, 2007

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A40	09/615,154	07/13/00	Mhashilkar <i>et al.</i>			07/13/00
	A41	2002/0183271	12/05/02	Chada <i>et al.</i>	514	44	12/07/01
	A42	2002/0091098	07/11/02	Fisher	514	44	11/21/01
	A43	2003/0147966	08/07/03	Franzen <i>et al.</i>	424	491	07/10/02
	A44	2003/0223938	12/04/03	Nagy <i>et al.</i>	424	46	04/14/03
	A45	2004/0009939	01/15/04	Chada <i>et al.</i>	514	44	03/03/03
	A46	2005/0101770	05/12/05	Presta	530	388.15	11/09/04
	A47	2005/0143336	06/30/05	Ramesh <i>et al.</i>	514	44	11/30/04
	A48	2006/0134801	06/22/06	Chada <i>et al.</i>	436	177	03/02/04
	A49	5,179,122	01/12/93	Greene <i>et al.</i>	514	458	02/11/91
	A50	5,747,469	05/05/98	Roth <i>et al.</i>	514	44	04/25/94
	A51	6,132,980	10/17/00	Wang <i>et al.</i>	435	7.23	09/28/98
	A52	6,168,791	01/02/01	Larsen <i>et al.</i>	424	158.1	05/21/98
	A53	6,407,218	06/18/02	Tamarkin <i>et al.</i>	530	389.1	11/10/98
	A54	60/661,680	03/14/05	Lin			03/14/05

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B11	WO 00/61626	10/19/00	WIPO	English
	B12	WO 01/60365	08/23/01	WIPO	English
	B13	WO 02/04511	01/17/02	WIPO	English
	B14	WO 02/45737	06/13/02	WIPO	English
	B15	WO 03/075952	09/18/03	WIPO	English

25746887.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B16	WO 03/087308	10/23/03	WIPO	English
	B17	WO 98/16655	04/23/98	WIPO	English
	B18	WO 98/35554	08/20/98	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C130	Albert <i>et al.</i> , "Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells," <i>Nat Immunol</i> , 2(11):1010-1017, 1998.
	C131	Alberts <i>et al.</i> "Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase," <i>J. Cell. Biochem. Supp.</i> , 22:18-23, 1995.
	C132	Alshafie <i>et al.</i> , "Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model," <i>Oncology Reports</i> , 7:1377-1381, 2000.
	C133	Barber, GN., "Host defense, viruses and apoptosis," <i>Cell Death Differ.</i> , 8(2):113-126, 2001.
	C134	Basu <i>et al.</i> , " Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer," <i>Mol. Cancer Res.</i> , 2:632-642, 2004.
	C135	Bedi <i>et al.</i> , "Inhibition of apoptosis during development of colorectal cancer," <i>Cancer Res.</i> , 55(9):1811-1816, 1995.
	C136	Benoit <i>et al.</i> , "Cardiac-specific transgenic overexpression of alpha1B-adrenergic receptors induce chronic activation of ERK MAPK signalling," <i>Biochem. Cell Biol.</i> , 82(6):719-727, 2004.
	C137	Benoit <i>et al.</i> , "Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2," <i>Oncogene</i> , 23:1631-1635, 2004.
	C138	Beretta <i>et al.</i> , "Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation," <i>EMBO J</i> , 15:658-664, 1996.
	C139	Beretta <i>et al.</i> , "Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection," <i>J. Virol</i> , 70:8993-8996, 1996.

25746887.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C140	Bonvini <i>et al.</i> , "Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription," <i>Cancer Res.</i> , 61:1671-1677, 2001.
	C141	Bowie <i>et al.</i> , "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> , 247(4948):1306-10, 1990
	C142	Chada <i>et al.</i> , "Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism," <i>Mol. Ther.</i> , 10(6):1085-1095, 2004.
	C143	Chada <i>et al.</i> , "MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family," <i>Int. Immunopharmacol.</i> , 4:649-667, 2004.
	C144	Chada <i>et al.</i> , "The multifunctional mda-7 gene encodes both tumor suppressor and TH1 cytokine (IL-24) activities," <i>Cancer Gene Therapy</i> , 10:S3, 2003
	C145	Chattergoon <i>et al.</i> , "Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis," <i>Nat Biotechnol.</i> , 18(9):974-979, 2000.
	C146	Craven <i>et al.</i> , "A decade of tyrosine kinases: from gene discovery to therapeutics," <i>Surg. Oncol.</i> , 12(1):39-49, 2003.
	C147	Cross <i>et al.</i> , "A p53-dependent mouse spindle checkpoint," <i>Science</i> , 267:1353-1356, 1995.
	C148	Cunningham <i>et al.</i> , "Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study," <i>Molecular Therapy</i> , 11(1):149-159, 2005. (Written in 2003 with Applicant)
	C149	Daigo <i>et al.</i> , "Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3," <i>Cancer Research</i> , 59:1966-1972, 1999.
	C150	Database accession No. U70824, GenBank.
	C151	Database accession No. U70880, GenBank.
	C152	Database UniProt, "Interleukin-24 precursor (suppression of tumorigenicity 16 protein) (melanoma differentiation-associated gene 7 protein) (MDA-7)," UniProt accession no.: Q13007, 2004.
	C153	Denkert <i>et al.</i> , "Prognostic impact of cyclooxygenase-2 in breast cancer," <i>Clin. Breast Cancer</i> , 4(6):428-433, 2004.

25746887.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C154	Donze <i>et al.</i> , "The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR," <i>EMBO J.</i> , 20:3771-3780, 2001.
	C155	Dumoutier and Renaud, "Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions," <i>Eur Cytokine Netw.</i> , 13(2):5-15, 2002.
	C156	Earnest <i>et al.</i> , "Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention," <i>J. Cell Biochem. Suppl.</i> , 161:156-166, 1992.
	C157	El-Rayes <i>et al.</i> , "Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines," <i>Mol. Cancer Ther.</i> , 3:1421-1426, 2004.
	C158	Fariss <i>et al.</i> , "The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds," <i>Cancer Res.</i> , 54:3346-3351, 1994.
	C159	Feng <i>et al.</i> , "Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase," <i>Proc. Natl. Acad. Sci., USA</i> , 89:5447-5451, 1992.
	C160	Fisher <i>et al.</i> , "mda-7/LI-24, a novel cancer selective apoptosis inducing cytokine gene," <i>Cancer Biol Therapy</i> , 2(4 suppl. 1):S24-S37, 2003.
	C161	Fraley <i>et al.</i> , "Entrapment of a bacterial plasmid in phospholipid vesicles: potential for gene transfer," <i>Proc. Natl. Acad. Sci. USA</i> , 76:3348-3352, 1979.
	C162	Gale <i>et al.</i> , "Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase," <i>J. Virol.</i> , 7(8):6505-6516, 1999.
	C163	Gale <i>et al.</i> , "Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation," <i>Mol. Cell Biol.</i> , 18:5208-5218, 1998.
	C164	Gale <i>et al.</i> , "Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance," <i>Clinical and Diagnostic Virology</i> , 10:157-162, 1998.
	C165	Gale <i>et al.</i> , "Translational control of viral gene expression in Eukaryotes," <i>Microbiol Mol Biol Rev.</i> , 64(2):239-280, 2000.
	C166	Gann <i>et al.</i> , "Low-dose aspirin and incidence of colorectal tumors in a randomized trial," <i>J. Natl. Cancer Inst.</i> , 85:1220-1224, 1993.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C167	Garn <i>et al.</i> , "IL-24 is expressed by rat and human macrophages," <i>Immunobiol</i> , 205:321-334, 2002.
	C168	Garner <i>et al.</i> , "Celecoxib for rheumatoid arthritis," <i>Cochrane Database Syst Rev.</i> , (4):CD003831, 2002. (abstract only)
	C169	Gething and Sambrook, "Protein folding in the cell," <i>Nature</i> , 355(6355):33-45, 1992.
	C170	Giovannucci <i>et al.</i> , "Aspirin use and the risk for colorectal cancer and adenoma in male health professionals," <i>Ann. Intern. Med.</i> , 121:241-246, 1994.
	C171	Giovannucci <i>et al.</i> , "Physical activity, obesity, and risk of colorectal adenoma in women (United States)," <i>Cancer Causes Control</i> , 7(2):253-63, 1996. (abstract only)
	C172	Greenberg <i>et al.</i> , "Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group," <i>J. Natl. Cancer Inst.</i> , 85:912-916, 1993.
	C173	Hanif <i>et al.</i> , "Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pat," <i>Biochemical Pharmacology</i> , (52):237-245, 1996.
	C174	Harris <i>et al.</i> , "Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor," <i>Caplus</i> , Abstract Number: 2000:282718, 2000.
	C175	Howe <i>et al.</i> , "Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer," <i>Cancer Res.</i> , 62:5405-5407, 2002.
	C176	Howe <i>et al.</i> , "Cyclooxygenase-2: a target for the prevention and treatment of breast cancer," <i>Endocr. Relat. Cancer</i> , 8:97-114, 2001.
	C177	Ji <i>et al.</i> , "Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo," <i>Cancer Research</i> , 62:2715-2720, 2002
	C178	Judware <i>et al.</i> , "Partial characterization of a cellular factor that regulates the double-stranded RNA-dependent eIF-2 α kinase in 3T3-F442A fibroblasts," <i>Mol. Cell Biol.</i> , 11(6):3259-3267, 1991.
	C179	Kamal <i>et al.</i> , "A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors," <i>Nature</i> , 425:407-410, 2003.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C180	Kaufman, "Orchestrating the unfolded protein response in health and disease," <i>J. Clin Invest.</i> , 110(10):1389-1398, 2002.
	C181	Killary <i>et al.</i> , "Definition of a tumor suppressor locus within human chromosome 3p21-p22," <i>Proc Nat Acad Sci USA</i> , 89:10877-10881, 1992.
	C182	Kismet <i>et al.</i> , "Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention," <i>Cancer Detect Prev.</i> , 28(2):127-42, 2004.
	C183	Kline <i>et al.</i> , "Vitamin E: mechanisms of action as tumor cell growth inhibitors," In: <i>Proceeding of the International Conference on Nutrition and Cancer</i> , Prasad and Cole (Eds.), Amsterdam: IOS Press, 37-53, 1998.
	C184	Kline <i>et al.</i> , "Vitamin E: mechanisms of action as tumor cell growth inhibitors," <i>J. Nutr.</i> , 131: 161S-163S, 2001.
	C185	Koehne and Dubois, "COX-2 inhibition and colorectal cancer," <i>Semin. Oncol.</i> , 31(2 Suppl 7):12-21, 2004.
	C186	Kulp <i>et al.</i> , "3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells," <i>Cancer Res.</i> , 64:1444-1451, 2004.
	C187	Kumar <i>et al.</i> , "Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF- κ B," <i>EMBO J</i> , 16:406-416, 1997.
	C188	Kumar <i>et al.</i> , "Double-stranded RNA-dependent protein kinase activates transcription factor NF- κ B by phosphorylating I κ B," <i>Proc. Natl. Acad. Sci., USA</i> , 91:6288-6292, 1994.
	C189	Le <i>et al.</i> , "Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling," <i>J. Biol. Chem.</i> , 280(3):2092-2104, 2005.
	C190	Lebedeva <i>et al.</i> , "Restoring apoptosis as a strategy for cancer gene therapy: focus on <i>p53</i> and <i>mda-7</i> ," <i>Semin Cancer Biol.</i> , 13(2):169-178, 2003.
	C191	Lenardo <i>et al.</i> , "The involvement of NF- κ B in β -interferon gene regulation reveals its role as widely inducible mediator of signal transduction," <i>Cell</i> , 57:287-294, 1989.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C192	Leng <i>et al.</i> , "Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis," <i>Hepatology</i> , 38:756-768, 2003.
	C193	Lerman <i>et al.</i> , "The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium," <i>Cancer Research</i> , 60:6116-6133, 2000.
	C194	Liu <i>et al.</i> , "Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth," <i>Am. J. Clin. Oncol.</i> , 26:S103-109, 2003.
	C195	Lupulescu, "Control of precancer cell transformation into cancer cells: its relevance to cancer prevention," <i>Cancer Detect. Prev.</i> , 20(6):634-637, 1996.
	C196	Malafa and Neitzel, "Vitamin E succinate promotes breast cancer tumor dormancy," <i>J. Surg. Res.</i> , 93:163-170, 2000.
	C197	Malafa <i>et al.</i> , "Vitamin E inhibits melanoma growth in mice," <i>Surgery</i> , 131:85-91, 2002.
	C198	Maloney and Workman, "HSP90 as a new therapeutic target for cancer therapy: the story unfolds," <i>Expert Opin. Biol. Ther.</i> , 2:3-24, 2002. (abstract only)
	C199	Mandler <i>et al.</i> , "Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates," <i>Bioconjug. Chem.</i> , 13(4):786-791, 2002.
	C200	Maniotis <i>et al.</i> , "Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry," <i>Am. J. Pathology</i> , 155:739-752, 1999.
	C201	Maran <i>et al.</i> , "Blockage of NF- κ B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras," <i>Science</i> , 265:789-792, 1994.
	C202	McKenzie <i>et al.</i> , "Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells," <i>Surgery</i> , 136:437-442, 2004.
	C203	Merrick and Hershey, "The pathway and mechanism of eukaryotic protein synthesis," In: <i>Translational Control</i> , Hershey <i>et al.</i> , (Eds.), Cold Spring Harbor Laboratory Press, NY, 31-69, 1996.
	C204	Meurs <i>et al.</i> , "Molecular cloning and characterization of the human double-stranded RNA-activated protein kinases induced by interferon," <i>Cell</i> , 62:379-390, 1990.

25746887.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C205	Meurs <i>et al.</i> , "Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase," <i>Proc. Natl. Acad. Sci., USA</i> , 90:232-236, 1993.
	C206	Mhashilkar <i>et al.</i> , "MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells." <i>Mol. Ther.</i> , 8:207-219, 2003.
	C207	Mizuguchi and Kay, "Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method," <i>Human Gene Therapy</i> , 9:2577-2583, 1998.
	C208	Narisawa <i>et al.</i> , "Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment," <i>Cancer Res.</i> , 41(5):1954-1957, 1981.
	C209	Neckers <i>et al.</i> , "Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity," <i>Invest New Drugs</i> , 17:361-373, 1999.
	C210	Nemunaitis <i>et al.</i> , "Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial," <i>Cancer Res.</i> , 60:6359-6366, 2000.
	C211	Nemunaitis, "Use of macrophage colony-stimulating factor in the treatment of fungal infections," <i>Clin Infect Dis</i> , 26(6):1279-1281, 1998.
	C212	Neuzil <i>et al.</i> , "Selective cancer cell killing by α -tocopheryl succinate," <i>Br. J. Cancer</i> , 84:87-89, 2000.
	C213	Nicolau and Sene, "Liposome-mediated DNA transfer in eukaryotic cells. Dependence of the transfer efficiency upon the type of liposomes used and the host cell cycle stage," <i>Biochim. Biophys. Acta</i> , 721:185-190, 1982.
	C214	Nicolau <i>et al.</i> , "Liposomes as carriers for in vivo gene transfer and expression," <i>Methods Enzymol.</i> , 149:157-176, 1987.
	C215	Oh <i>et al.</i> , "Conservation between animals and plants of the <i>cis</i> -acting element involved in the unfolded protein response," <i>Biochem Biophys Res Commun</i> , 301:225-230, 2003.
	C216	Pavio <i>et al.</i> , "Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the Eukaryotic initiation factor 2 α kinase PERK," <i>J. Virol</i> , 77(6):3578-3585, 2003.
	C217	Petryshyn <i>et al.</i> , "Detection of activated double-stranded RNA-dependent protein kinase in 3T3-F442A cells," <i>Proc. Natl. Acad. Sci., USA</i> , 85(5):1427-1431, 1988.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C218	Petryshyn <i>et al.</i> , "Growth-related expression of a double-stranded RNA-dependent protein kinase in 3T3 cells," <i>J. Biol. Chem.</i> , 259(23):14736-14742, 1984.
	C219	Pezzella <i>et al.</i> , "Non-Small-Cell Lung Carcinoma Tumor Growth without Morphological Evidence of Neo-Angiogenesis," <i>Am. J. Pathology</i> , 151:1417-1423, 1997.
	C220	Piazza <i>et al.</i> , "Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis," <i>Cancer Res.</i> , 55(14):3110-6, 1995.
	C221	Piazza <i>et al.</i> , "Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction," <i>Cancer Res.</i> , (57):2452-59, 1997.
	C222	Piazza <i>et al.</i> , "Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels," <i>Cancer Res.</i> , (57):2909-2915, 1997.
	C223	Prasad and Edwards-Prasad, "Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture," <i>Cancer Res.</i> , 42:550-554, 1982.
	C224	Prasad and Edwards-Prasad, "Vitamin E and cancer prevention: recent advances and future potentials," <i>J. Am. Coll. Nutr.</i> , 11:487-500, 1992.
	C225	Ramesh <i>et al.</i> , "Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery," <i>DNA and Cell Biol.</i> , 23:850-857, 2004.
	C226	Rao <i>et al.</i> , "Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent," <i>Cancer Res.</i> , 55(7):1464-1472, 1995.
	C227	Reddy <i>et al.</i> , "Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet," <i>Cancer Res.</i> , (50):2562-2568, 1990.
	C228	Restifo <i>et al.</i> , "Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity," <i>Curr Opin Immunol</i> , 12(5):597-603, 2000.
	C229	Ron, "Translational control in the endoplasmic reticulum stress response," <i>J. Clin Invest</i> , 110(10):1383-1388, 2002.
	C230	Ross <i>et al.</i> , "The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy," <i>Oncologist</i> , 8(4):307-25, 2003.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C231	Rudinger, "Characteristics of the amino acids as components of a peptide hormone sequence," <i>Peptide Hormones</i> , University Park Press, 1-7, June 1976.
	C232	Sakariassen <i>et al.</i> , "Angiogenesis-independent tumor growth mediated by stem-like cancer cells," <i>Proc. Natl. Acad. Sci. USA</i> , 103:16466-16471, 2006.
	C233	Sarkar <i>et al.</i> , "mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK," <i>Proc. Natl. Acad. Sci. USA</i> , 99(15):10054-10059, 2002.
	C234	Sausville <i>et al.</i> , "Clinical development of 17-allylamino, 17-demethoxygeldanamycin," <i>Curr. Cancer Drug Targets</i> , 3:377-383, 2003.
	C235	Schaefer <i>et al.</i> , "Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo," <i>Cell Immunol.</i> , 214:110-122, 2001.
	C236	Schulte and Neckers, "The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin," <i>Cancer Chemother. Pharmacol.</i> , 42(4):273-279, 1998.
	C237	Schwartz and Shklar, "The selective cytotoxic effect of carotenoids and alpha-tocopherol on human cancer cell lines in vitro," <i>J. Oral Maxillofac. Surg.</i> , 50:367-373, 1992.
	C238	Shtrichman <i>et al.</i> , "Tissue selectivity of interferon-stimulated gene expression in mice infected with dam ⁺ versus dam ⁻ <i>salmonella enterica</i> serovar typhimurium strains," <i>Infect Immun</i> , 70:5579-5588, 2002.
	C239	Singh and Lippman, "Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents," <i>Oncology (Williston Park)</i> , 12(12): 1787-800, 1998.
	C240	Singh and Reddy, "Molecular markers in chemoprevention of colon cancer," <i>Annals. NY Acad. Sci.</i> , (768):205-209, 1995.
	C241	Singh <i>et al.</i> , "Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis," <i>Carcinogenesis</i> , (15):1317-1323, 1994.
	C242	Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>TIB Tech</i> , 18:34-39, 2000.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C243	Steinbach <i>et al.</i> , "The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis," <i>N. Engl. J. Med.</i> , 342:1946-1952, 2000.
	C244	Su <i>et al.</i> , "Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene," <i>Cancer Res.</i> , 58, 2339-2342, 1998.
	C245	Sudhakar <i>et al.</i> , "Phosphorylation of serine 51 in initiation factor 2 α (eIF2 α) promotes complex formation between eIF2 α (P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B," <i>Biochemistry</i> , 39(42):12929-12938, 2000.
	C246	Taylor and Kingston, "E1a transactivation of human HSP70 gene promoter substitution mutants is independent of the composition of upstream and TATA elements," <i>Mol. Cell. Biol.</i> , 10:176, 1990.
	C247	Taylor and Kingston, "Factor substitution in a human HSP70 gene promoter: TATA-dependent and TATA-independent interactions," <i>Mol. Cell. Biol.</i> , 10:165, 1990.
	C248	Thompson <i>et al.</i> , "Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac," <i>J. Natl. Cancer Inst.</i> , 87(16):1259-1260, 1995.
	C249	Thun <i>et al.</i> , "Aspirin use and reduced risk of fatal colon cancer," <i>N. Engl. J. Med.</i> , 325(23):1593-1596, 1991.
	C250	Todd <i>et al.</i> , "An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo," <i>Oncogene</i> , 13:2387-2396, 1996.
	C251	Tomizawa <i>et al.</i> , "Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B," <i>P Nat Acad Sci USA</i> , 98:13954-13959, 2001.
	C252	Tong <i>et al.</i> , "Immune activation by Ad-mda7 (INGN 241) gene transfer in advanced patients," <i>Cancer Gene Therapy</i> , 10:S37, 2002.
	C253	Vattem <i>et al.</i> , "Inhibitory sequences in the N-terminus of the double-stranded-RNA-dependent protein kinase, PKR, are important for regulating phosphorylation of eukaryotic initiation factor 2 α (eIF2 α)," <i>Eur J Biochem</i> , 268(4):1143-1153, 2001.
	C254	Vermeulen <i>et al.</i> , "Lack of angiogenesis in lymph node metastases of carcinomas is growth pattern-dependent," <i>Histopathology</i> , 40:105-107, 2002.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-2</i>	Other Art <i>See Page 2-12</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C255	Whitesell <i>et al.</i> , "Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation," <i>Proc. Natl. Acad. Sci. USA</i> , 91(18):8324-8328, 1994.
	C256	Williams, "Signal integration via PKR," <i>Sci STKE</i> , 89:RE2, 2001. (abstract only)
	C257	Wu <i>et al.</i> , "Inhibitory effects of RRR-alpha-tocopheryl succinate on benzo(a)pyrene (B(a)P)-induced forestomach carcinogenesis in female mice," <i>World J. Gastroenterol.</i> , 7:60-65, 2001.
	C258	Yeo <i>et al.</i> , "Accumulation of unglycosylated liver secretory glycoproteins in the rough endoplasmic reticulum," <i>Biochem Biophys Res Commun</i> , 160(3):1421-1428, 1989.
	C259	You <i>et al.</i> , "Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells," <i>Mol. Carcinogenesis</i> , 33(4):228-236, 2002.
	C260	You <i>et al.</i> , "RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation," <i>Cell Growth Differ.</i> , 12:471-480, 2001.
	C261	Yu <i>et al.</i> , "Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells," <i>Cancer Res.</i> , 61(17):6569-6576, 2001.

25746887.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.